Cardiome Announces The Addition Of Dr. Steen Juul-Möller As Medical Director, Europe

Cardiome Announces The Addition Of Dr. Steen Juul-Möller As Medical Director,
                                    Europe

PR Newswire

VANCOUVER, March 28, 2013

NASDAQ: CRME TSX: COM

VANCOUVER, March 28, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:  CRME) 
(TSX:  COM)  today  announces  the   addition  of  Steen  Juul-Möller,   M.D., 
Ph.D./DMSc., FESC to Cardiome's management team as Medical Director,  Europe. 
In his capacity of Medical  Director, Dr. Juul-Möller will oversee  Cardiome's 
clinical and medical affairs activities.

Dr. Juul-Möller  has  held  his  clinical position  at  the  Malmö  University 
Hospital (now Skåne University Hospital) since 1980. He is a strong  proponent 
for the rapid cardioversion of patients with recent onset atrial  fibrillation 
(AF). Dr. Juul-Möller  was responsible for  changing his hospital's  emergency 
room AF management protocol  and developed an  AF fast-track treatment  system 
where patients were safely and rapidly cardioverted resulting in both  patient 
and  economic  benefits.  Vernakalant  was   regularly  used  in  the   atrial 
fibrillation  fast-track   protocol.  Since   BRINAVESS™  was   available   in 
Sweden,clinicians at  Skåne University  Hospital haveused  it to  cardiovert 
over 250  recent onset  atrial fibrillation  patients to  normal sinus  rhythm 
achieving successful cardioversion in 70% to 80% of patients, which is  almost 
50% higher than what was  achieved in clinical trials.  He has also served  on 
the Steering Committee of both  the ACT I and ACT  III pivotal Phase 3  trials 
for vernakalant.

"We are thrilled to have Dr.  Juul-Möller join Cardiome's medical team,"  said 
Bill Hunter,  M.D.,  Cardiome's President  and  CEO. "Sharing  his  BRINAVESS™ 
experience  with   other  clinicians   and  decision   makers  such   as   the 
identification of  patients  who would  best  respond to  BRINAVESS™  and  the 
economic benefits his hospital has  gained after implementing a fast-track  AF 
protocol  will  be  key  as  Cardiome  assumes  BRINAVESS™   commercialization 
activities."

In addition to clinical practice, he has concentrated his research  activities 
on clinical cardiology. He successfully ran a large clinical project involving
94 centers in Sweden, the results of which were singularly responsible for the
1997 FDA  recommendation  of  aspirin  treatment  for  primary  prevention  of 
myocardial infarction  in patients  with stable  angina (published  in  Lancet 
1992;340:1421-1425).

For the  last 10  years, Dr.  Juul-Möller has  directed his  research  towards 
arrhythmias and international  drug development including  Phase 2 through  to 
Phase 4 clinical studies, frequently utilizing the state-of-the-art Laboratory
for Ambulatory ECG Monitoring. He has had an instrumental role in creating the
first  Scandinavian  Syncope  Center,  located  in  Malmö  and  developing   a 
fast-track atrial fibrillation treatment program at his hospital.

About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the
discovery, development and commercialization of new therapies that will
improve the health of patients around the world. Cardiome has one marketed
product, BRINAVESS™ (vernakalant IV), approved in Europe and other territories
for the rapid conversion of recent onset atrial fibrillation to sinus rhythm
in adults.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock
Exchange (COM). For more information, please visit our web site at
www.cardiome.com.

Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions.
Forward- looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for the remainder of 2013 and beyond,
our strategies or future actions, our targets, expectations for our financial
condition and the results of, or outlook for, our operations, research and
development and product and drug development. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following: general
economic and business conditions in the United States, Canada, Europe, and the
other regions in which we operate; market demand; technological changes that
could impact our existing products or our ability to develop and commercialize
future products; competition; existing governmental legislation and
regulations and changes in, or the failure to comply with, governmental
legislation and regulations; availability of financial reimbursement coverage
from governmental and third-party payers for products and related treatments;
adverse results or unexpected delays in pre-clinical and clinical product
development processes; adverse findings related to the safety and/or efficacy
of our products or products; decisions, and the timing of decisions, made by
health regulatory agencies regarding approval of our technology and products;
the requirement for substantial funding to expand commercialization
activities; and any other factors that may affect our performance. In
addition, our business is subject to certain operating risks that may cause
any results expressed or implied by the forward-looking statements in this
presentation to differ materially from our actual results. These operating
risks include: our ability to attract and retain qualified personnel; our
ability to successfully complete pre-clinical and clinical development of our
products; changes in our business strategy or development plans; intellectual
property matters, including the unenforceability or loss of patent protection
resulting from third-party challenges to our patents; market acceptance of our
technology and products; our ability to successfully manufacture, market and
sell our products; the availability of capital to finance our activities; and
any other factors described in detail in our filings with the Securities and
Exchange Commission available at www.sec.gov and the Canadian securities
regulatory authorities at www.sedar.com. Given these risks, uncertainties and
factors, you are cautioned not to place undue reliance on such forward-looking
statements and information, which are qualified in their entirety by this
cautionary statement. All forward-looking statements and information made
herein are based on our current expectations and we undertake no obligation to
revise or update such forward-looking statements and information to reflect
subsequent events or circumstances, except as required by law.

SOURCE Cardiome Pharma Corp.

Contact:

Cardiome Investor Relations
(604) 676-6993 or Toll Free: 1-800-330-9928
Email:ir@cardiome.com